Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 2件: PML, RARA 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
2 Adherens junction 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
3 Adipocytokine signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
4 Adipocytokine signaling pathway 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
5 Adipocytokine signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
6 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
7 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
9 Alcoholic liver disease 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
10 Alcoholic liver disease 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
11 Alcoholic liver disease 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
12 Alcoholic liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
13 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
14 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
15 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
16 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
17 AMPK signaling pathway 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
18 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
19 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
20 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
21 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
22 Arrhythmogenic right ventricular cardiomyopathy 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
23 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
24 Bile secretion 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
25 Bile secretion 💬
 1件: NR1H4 💬 D00734 💬 Ursodeoxycholic acid 14件:  6 ,  8 , 20, 46, 67, 84, 93, 94, 95, 96, 97, 234, 296, 299 💬
26 Bladder cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
27 Breast cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
28 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
29 Calcium signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
30 cAMP signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
31 cAMP signaling pathway 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
32 cAMP signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
33 Cell adhesion molecules 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
34 Central carbon metabolism in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
35 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
36 Chemical carcinogenesis - reactive oxygen species 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
37 Chemical carcinogenesis - receptor activation 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
38 Chemical carcinogenesis - receptor activation 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
39 Chemical carcinogenesis - receptor activation 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
40 Chemical carcinogenesis - receptor activation 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
41 Chemokine signaling pathway 💬
 2件: CCR2, CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
42 Choline metabolism in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
43 Colorectal cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
44 Coronavirus disease - COVID-19 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
45 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
46 Cushing syndrome 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
47 Cytokine-cytokine receptor interaction 💬
 2件: CCR2, CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
48 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
49 Diabetic cardiomyopathy 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
50 Diabetic cardiomyopathy 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
51 Diabetic cardiomyopathy 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
52 Dilated cardiomyopathy 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
53 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
54 Drug metabolism - other enzymes 💬
 2件: IMPDH1, IMPDH2 💬 D01392 💬 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224 💬
55 Drug metabolism - other enzymes 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
56 ECM-receptor interaction 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
57 EGFR tyrosine kinase inhibitor resistance 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
58 Endocrine resistance 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
59 Endocytosis 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
60 Endocytosis 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
61 Endocytosis 💬
 1件: PML 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
62 Endometrial cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
63 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
64 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
65 ErbB signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
66 Estrogen signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
67 Estrogen signaling pathway 💬
 1件: RARA 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
68 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
69 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
70 Focal adhesion 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
71 Focal adhesion 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
72 FoxO signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
73 Gap junction 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
74 Gastric cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
75 Gastric cancer 💬
 1件: RARB 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
76 Glioma 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
77 Glucagon signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
78 Glucagon signaling pathway 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
79 Glucagon signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
80 Glutathione metabolism 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
81 GnRH signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
82 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
83 Hematopoietic cell lineage 💬
 1件: ITGA4 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
84 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 D02994 💬 Rituximab 48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
85 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
86 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
87 Hepatitis C 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
88 Hepatitis C 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
89 Hepatitis C 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
90 Hepatitis C 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
91 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
92 Hepatocellular carcinoma 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
93 Herpes simplex virus 1 infection 💬
 1件: PML 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
94 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
95 HIF-1 signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
96 Human cytomegalovirus infection 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
97 Human cytomegalovirus infection 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
98 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
99 Human immunodeficiency virus 1 infection 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
100 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
101 Human papillomavirus infection 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
102 Human papillomavirus infection 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
103 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
104 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
105 Huntington disease 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
106 Hypertrophic cardiomyopathy 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
107 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
108 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
109 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
110 Influenza A 💬
 1件: PML 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
111 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
112 Insulin resistance 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
113 Insulin resistance 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
114 Insulin resistance 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
115 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
116 Intestinal immune network for IgA production 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
117 JAK-STAT signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
118 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
119 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
120 Leishmaniasis 💬
 1件: ITGA4 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
121 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
122 Leukocyte transendothelial migration 💬
 1件: ITGA4 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
123 Lipid and atherosclerosis 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
124 Lipid and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
125 Longevity regulating pathway 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
126 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
127 MAPK signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
128 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
129 Melanoma 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
130 Metabolic pathways 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
131 Metabolic pathways 💬
 2件: IMPDH1, IMPDH2 💬 D01392 💬 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224 💬
132 Metabolic pathways 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
133 MicroRNAs in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
134 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
135 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
136 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
137 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00246 💬 Budesonide 9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 💬
138 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
139 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
140 Non-alcoholic fatty liver disease 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
141 Non-alcoholic fatty liver disease 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
142 Non-alcoholic fatty liver disease 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
143 Non-alcoholic fatty liver disease 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
144 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
145 Non-small cell lung cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
146 Non-small cell lung cancer 💬
 1件: RARB 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
147 Nucleotide metabolism 💬
 2件: IMPDH1, IMPDH2 💬 D01392 💬 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224 💬
148 Nucleotide metabolism 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
149 Osteoclast differentiation 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
150 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
151 Oxytocin signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
152 Pancreatic cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
153 Parathyroid hormone synthesis, secretion and action 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
154 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
155 Pathways in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
156 Pathways in cancer 💬
 3件: PML, RARA, RARB 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
157 Pathways in cancer 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
158 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
159 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
160 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
161 Phospholipase D signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
162 PI3K-Akt signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
163 PI3K-Akt signaling pathway 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
164 PPAR signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
165 PPAR signaling pathway 💬
 1件: PPARA 💬 D11208 💬 Elafibranor 2件: 93, 94 💬
166 PPAR signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
167 PPAR signaling pathway 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
168 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
169 Prostate cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
170 Proteoglycans in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
171 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
172 Purine metabolism 💬
 2件: IMPDH1, IMPDH2 💬 D01392 💬 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224 💬
173 Purine metabolism 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
174 Pyrimidine metabolism 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
175 Rap1 signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
176 Ras signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
177 Regulation of actin cytoskeleton 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
178 Regulation of actin cytoskeleton 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
179 Relaxin signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
180 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
181 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
182 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
183 Shigellosis 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
184 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
185 Small cell lung cancer 💬
 1件: RARB 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
186 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
187 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
188 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
189 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
190 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
191 Th17 cell differentiation 💬
 1件: RARA 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
192 Thermogenesis 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
193 Thyroid cancer 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
194 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
195 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
196 Toxoplasmosis 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
197 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
198 Transcriptional misregulation in cancer 💬
 1件: ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
199 Transcriptional misregulation in cancer 💬
 2件: PML, RARA 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
200 Transcriptional misregulation in cancer 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
201 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
202 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
203 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
204 Ubiquitin mediated proteolysis 💬
 1件: PML 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
205 Viral carcinogenesis 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
206 Viral life cycle - HIV-1 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
207 Viral protein interaction with cytokine and cytokine receptor 💬
 2件: CCR2, CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
208 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
209 Virion - Human immunodeficiency virus 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
210 Yersinia infection 💬
 1件: ITGA4 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
211 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ